Overview
V-Bio Ventures is a Belgian Venture Capital firm specializing in life sciences and biotech. The fund invests primarily in Belgian and European companies developing novel therapeutics, diagnostics, and biotechnology platforms.
As one of the dedicated life sciences VCs in Belgium, V-Bio Ventures operates alongside funds like imec.xpand (deep tech) and PMV (ParticipatieMaatschappij Vlaanderen) (government) to finance the Belgian biotech cluster that generated $97M in funding in 2025.
In the news
- What happens when R&D optimism meets revenue reality? For science startups, the transition from R&D to commercialization brings a whole new set of financial challenges. So how can companies and investors prepare — and avoid a cash crunch when things don’t go according to plan? In our latest V-Bio Views article, Willem Broekaert shares his perspective on navigating this critical transition, building financial resilience, and preparing for the unexpected. As he puts it: you need to build your shelter before the weather turns
- BioSpace just dropped their latest episode of the Denatured Podcast. Featuring none other than Christina Takke, tune in for an in depth discussion on the biotech ecosystem in the Benelux, what works, what needs work, a must listen. https://lnkd.in/eApY9GyD
- Did you catch our latest newsletter? It’s packed with news and insights from across the V-Bio Ventures fund and portfolio — from major company milestones to our take on the ideas and innovations that are shaping the future of life sciences. In each edition, you’ll find: 🌟 Portfolio news — including deals, partnerships, clinical trial updates, and other key milestones 💡 V-Bio Views — perspectives from our team on the investment trends, scientific breakthroughs, and emerging technologies that have caught our attention 🎙️
- Protealis just launched their interactive Soy Map of Europe. A one stop shop for anyone who wants to see where and how you can integrate protein crops into your rotation. Wonderful tool, great company!
- Our colleagues Christina Takke and Katja Rosenkranz will be attending Biocentury Grand Rounds on September 23rd-25th. Join us to discuss what happens at the cutting edge of translational science and how to bring innovative medicines to patients.
- V-Bio Ventures portfolio company Tanai Therapeutics just announced the appointment of Josua Jordi as its new CEO. We are excited to welcome Josua in his new position and are excited to be a witness of the company's future. Metabolic disease is at the root of many modern day ailments and new modalities are sorely needed to get this modern plague under control. https://lnkd.in/edYQbj6k
- Our partners Shelley Margetson and 🧪 Ward Capoen will be attending IPEM Global in Paris next month. Come say hello and learn about V-Bio Ventures and how we bring finance and expertise to the next biotech success stories. See you in Paris!
- another significant milestone for Agomab today. The company announces the design of its NOV-ERA Phase 2b study in Fibrostenosing Crohn's Disease. This will be the first time a drug is tested in this indication, with a fit for purpose endpoint. Great to see our portfolio company forging ahead and exploring new territory!
Something wrong or missing? Send an update. Fixed within 24 hours.